AAPG

Ascentage Pharma Group International (AAPG) Business Model Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Model

High gross margin profile at 84.1% suggests a strong core product/service mix.

Revenue generation remains weak on a per-share basis relative to the current valuation, with revenue per share at 6.13 and price-to-sales at 20.67.

Profitability

Operating performance remains deeply negative, with EBIT margin at -210.4% and net profit margin at -216.7%.

Returns are severely negative, including ROA at -31.0%, ROE at -123.6%, and ROIC at -33.7%.

Cash Conversion

Free cash flow remains negative, with free cash flow yield at -10.6% and free cash flow to firm at -1.21B.

Cash conversion is poor despite a current ratio of 1.79, with operating cash flow margin at -213.4% and cash conversion cycle at -153.2 days.

Balance Sheet Support

Liquidity appears adequate with a current ratio of 1.79 and cash ratio of 1.50.

Leverage is manageable at the enterprise level, with net debt to EBITDA at 0.44 and debt to capital at 59.9%.

Scalability Operating Leverage

The business shows limited operating leverage because high gross margin is not translating into positive EBIT or EBITDA margins.

Working capital efficiency is mixed, with inventory turnover at 3.15 and days of sales outstanding at 162.7 days.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ascentage Pharma Group International. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →